Enhanced Risk Stratification in Stage I Melanoma Patients Achieved Using DecisionDx-Melanoma Test Over Traditional AJCC8 Methodology

Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Study Shows DecisionDx-Melanoma Provides Prognostic Information on Survival Outcomes

Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology &nbsp Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes &nbsp FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovati..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms